Status:
UNKNOWN
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
Lead Sponsor:
INanoBio Inc.
Collaborating Sponsors:
TMC HealthCare
Conditions:
COVID-19
SARS-CoV-2 Infection
Eligibility:
All Genders
18+ years
Brief Summary
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment. The p...
Detailed Description
A longitudinal, non-randomized study to evaluate the utility of the INanoBio's protein arrays in detecting unique antibodies in COVID-19 patients. To study the feasibility of utilizing a viral proteom...
Eligibility Criteria
Inclusion
- Subject must meet all of the following criteria to be eligible for treatment in the study:
- Subject or legal representative understands the nature of the procedure and has signed the Subject Informed Consent Form prior to study procedures
- For the COVID-19 Cohort
- Subject has lab-confirmed diagnosis of COVID-19 by RT-PCR
- For the PUI Cohort
- Subject has suspected COVID-19 according to medical evaluation, but does not yet have lab-confirmed diagnosis of COVID-19 (results outstanding, or has tested negative by RT-PCR)
Exclusion
- Subject or legal representative not willing to consent
Key Trial Info
Start Date :
July 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04465981
Start Date
July 3 2020
End Date
December 1 2022
Last Update
August 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
TMC HealthCare
Tucson, Arizona, United States, 85712